Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

RECRUITING

NCT05584631

PHASE1

IVIG vs SCIG in CIDP

Sponsor: Rutgers, The State University of New Jersey

View on ClinicalTrials.gov

Summary

Current dosing practices for immunoglobulin G (IgG) may be inadequate in extreme body weight. The current study will evaluate the influence of body composition on intravenous and subcutaneous administration of immunoglobulin G in patients.

Official title: The Influence of Body Composition on Immunoglobulin Disposition After Intravenous and Subcutaneous Administration

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

Start Date

2022-09-11

Completion Date

2026-12-01

Last Updated

2025-12-11

Healthy Volunteers

Conditions

CIDP Immunoglobulin Deficiency Chronic Inflammatory Demyelinating Polyneuropathy

Interventions

DRUG

Intravenous immune globulin G

Intravenous immune globulin G dosed based on the subjects's current dose received for the treatment of CIDP.

DRUG

Subcutaneous immune globulin G

Subcutaneous immune globulin G converted from the subject's current IVIG dose 1:1.

Locations (1)

Rutgers, The State University of New Jersey Clinical Research Center

New Brunswick, New Jersey, United States